Evidence map›Paper›PMID 41915009›Full record

ArticleInternational forum of allergy & rhinology2026

Recovery of Parosmia Preferentially Influences Longitudinal Improvement of Quality of Life in C19OD.

Tiana M Saak, Jeremy P Tervo, Brandon J Vilarello, Patricia T Jacobson, Francesco F Caruana, Liam W Gallagher, David A Gudis, Davangere P Devanand, Jonathan B Overdevest

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International forum of allergy & rhinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Tiana M SaakColumbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.ORCID https://orcid.org/0009-0006-6584-5866
Jeremy P TervoDepartment of Otolaryngology-Head and Neck Surgery, New York-Presbyterian/Columbia University Irving Medical Center, New York, New York, USA.ORCID https://orcid.org/0000-0002-8883-8566
Brandon J VilarelloDepartment of Otolaryngology-Head and Neck Surgery, University of Miami Miller School of Medicine, Miami, Florida, USA.
Patricia T JacobsonDepartment of Otolaryngology-Head and Neck Surgery, Yale School of Medicine, New Haven, Connecticut, USA.
Francesco F CaruanaDepartment of Otolaryngology-Head and Neck Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Liam W GallagherDepartment of Otolaryngology-Head and Neck Surgery, University of Minnesota, Minneapolis, Minnesota, USA.
David A GudisColumbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.ORCID https://orcid.org/0000-0002-1938-9349
Davangere P DevanandDepartment of Psychiatry, New York-Presbyterian/Columbia University Irving Medical Center, New York, New York, USA.
Jonathan B OverdevestColumbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.ORCID https://orcid.org/0000-0002-1152-2512

Funding

Neurocognitive & neuropsychiatric impact of chemosensory alterations: Implications of olfactory dysfunction in COVID-19K23DC019678 · NIDCD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI OVERDEVEST, JONATHAN B · 2021 to 2025
$893k
NIDCD NIH HHS K23 DC019678NIH HHS K23DC019678
6 · The paper itself

Abstract

backgroundPersistent COVID-associated olfactory dysfunction (C19OD) negatively impacts quality of life (QoL). This prospective longitudinal cohort study sought to determine which aspects of chemosensory recovery may preferentially influence QoL improvement in this population.

methodsIndividuals with C19OD (N = 100) completed chemosensory and QoL assessment with Sniffin' Sticks, Taste Assessment, Questionnaire of Olfactory Disorders-Negative Statements (QOD-NS), and QOD-PAR at baseline and 1 year. Multivariable analyses assessed baseline and longitudinal associations between chemosensory dysfunction and QOD-NS.

resultsQoL associated with TDI (Coef.; [CI]; p-value: -0.32; [-0.62, -0.032]; 0.030), threshold (-0.82; [-1.5, -0.14]; 0.019), QOD-Par (-1.0; [-0.20, -1.9]; 0.016), and self-reported gustatory dysfunction (GD) (-7.4; [-14, -0.46]; 0.037) at baseline assessment, though quantitative GD did not associate with QoL. Longitudinally, improvements in discrimination (-1.2; [-2.3, -0.18]; 0.023) and QOD-Par (-2.5; [-0.99, -4.1]; 0.002) scores were associated with improved QoL. Individuals with improved parosmia symptoms experienced a 12.86 (12.99, 0.040) QOD-NS point improvement from baseline compared to 5.91 (7.98, < 0.001) for those with persistent parosmia.

conclusionsIndependent of mental health, chemosensory function independently drives QoL in C19OD. Parosmia, low odor threshold, and patient-reported GD are all associated with poorer QoL at baseline. Longitudinally, the ability to differentiate among odors is an important correlate of improvement of smell-related QoL in C19OD patients, while parosmia is the strongest driver of longitudinal recovery of smell-related QoL in C19OD. Trending domain-specific olfactory performance in C19OD may allow for improved patient counseling and QoL prognosis.

Indexed as

COVID-19Olfaction DisordersQuality of LifeAdultAgedFemaleHumansLongitudinal StudiesMaleMiddle AgedProspective StudiesSARS-CoV-2SmellSurveys and QuestionnaireschemosensationCOVID‐19quality of lifesmell

Identifiers

PMID41915009
PMCPMC13544482

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.